Parisa Mashayekhi

Dr. Parisa Mashayekhi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MJMohammad Mehdi Jahani
Mohammad Mehdi Jahani
PMParisa Mashayekhi
Parisa Mashayekhi
MOMir Davood Omrani
Mir Davood Omrani
AMAzita Azimi Meibody
Azita Azimi Meibody
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and is often diagnosed at advanced stages, limiting treatment options. This systematic review aims to evaluate the efficacy of liquid biopsy in detecting genetic mutations in NSCLC, focusing on its sensitivity, specificity, clinical utility, and potential to guide personalized treatment strategies. A systematic search was conducted in PubMed, Scopus, Embase, Web of Science, and Cochrane Library to identify relevant studies published between 1990 and September 2024. Eligible studies included comparative analyses of liquid biopsy techniques for NSCLC diagnosis, prognosis, progression, or treatment response. This review adheres to the PRISMA 2020 guidelines and assesses study quality using the QUADAS framework. A total of 30 studies were included. Digital droplet PCR (ddPCR) demonstrated the highest sensitivity, detecting low-frequency mutations such as EGFR T790M at levels as low as 0.01%. Next-generation sequencing (NGS) provided comprehensive mutational profiling, revealing tumor heterogeneity and co-existing mutations but required high-quality plasma samples. The cobas EGFR Mutation Test, while less sensitive than ddPCR, remains widely used due to its clinical accessibility. Emerging methods, including extracellular vesicle analysis, show promise but require further validation. Additionally, liquid biopsy effectively identified non-EGFR mutations, such as KRAS, ALK, and MET amplifications, expanding its clinical applicability. Liquid biopsy is a transformative tool in NSCLC management, offering a minimally invasive approach for mutation detection, disease monitoring, and treatment guidance. Future research should focus on multicenter trials and emerging technologies to enhance clinical integration and broaden applicability across different cancer types.

1 July 2024 in Iranian Biomedical Journal
Verified
Journal Article
Open access
PDF file
MJMohammad Mehdi Jahani
Mohammad Mehdi Jahani
PMParisa Mashayekhi
Parisa Mashayekhi
MOMir Davood Omrani
Mir Davood Omrani
AKAdnan Khosravi
Adnan Khosravi
ADAli Dehghanifard
Ali Dehghanifard
PRParsa Rostami
Parsa Rostami
Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the ...

1 April 2025 in Advanced Biomedical Research
Verified
Journal Article
Open access
MJMohammad Mehdi Jahani
Mohammad Mehdi Jahani
PMParisa Mashayekhi
Parisa Mashayekhi
MOMir Davood Omrani
Mir Davood Omrani
AMAzita Azimi Meibodi
Azita Azimi Meibodi
This review systematically evaluated the literature on detecting epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) using plasma exosomal DNA by analyzing data from eight studies selected from a comprehensive literature search (PubMed, Embase, Web of Science; 2010–2024). The findings revealed a wide range of EGFR mutation prevalence (10%–26.8%) across studies, with most mutations located in exons 19 and 21. Comparative analysis highlighted the potential of plasma exosomal DNA (exDNA) as a non-invasive alternative to tissue biopsy, although significant heterogeneity in sensitivity and specificity was observed across liquid biopsy methods (including circulating tumor cells and exDNA analyses). This heterogeneity underscores the need for standardization and further validation to optimize the clinical utility of plasma exDNA in detecting EGFR mutations, monitoring treatment response, and identifying resistance mechanisms in NSCLC.

1 May 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
PMParisa Mashayekhi
Parisa Mashayekhi
MOMir Davood Omrani
Mir Davood Omrani
ZYZeynab Yassin
Zeynab Yassin
ADAli Dehghanifard
Ali Dehghanifard
LALeila Ashouri
Leila Ashouri
ZSZahra Shabanzadeh
Zahra Shabanzadeh
Background: As an emerging pandemic disease, COVID-19 encompasses a spectrum of clinical diagnoses, from the common cold to severe respiratory syndrome. Considering the shreds of evidence demonstrating the relationship between human leukocyte antigen (HLA) allele diversity and infectious disease susceptibility, this study was conducted to determine the association of HLA alleles with COVID-19 severity in Iranian subjects. Methods: In this case-control study, a total of 200 unrelated individuals (consisting of 100 people with severe COVID-19 and an average age of 55.54 as the case group, and 100 patients with mild COVID-19 with an average age of 48.97 as the control group) were recruited, and HLA typing (Locus A, B, and DR) was performed using the Olerup sequence-specific oligonucleotide (SSO) HLA-typing kit. Results: Our results showed that HLA-A*11 and HLA-DRB1*14 alleles were more frequently observed in severe COVID-19 cases, while HLA-B*52 was more common in mild cases, which was in agreement with some previous studies. Conclusion: Our results confirmed the evidence for the association of HLA alleles with COVID-19 outcomes. We found that HLA-A*11 and HLA-DRB1*14 alleles may be susceptibility factors for severe COVID-19, while HLA-B*52 may be a protective factor. These findings provide new insight into the pathogenesis of COVID-19 and help patient management.

26 September 2023 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
PMParisa Mashayekhi
Parisa Mashayekhi
MOMir Davood Omrani
Mir Davood Omrani
STSeyed Hasan Tonekaboni
Seyed Hasan Tonekaboni
ADAli Dehghanifard
Ali Dehghanifard
Basal cell nevus syndrome (BCNS), or Gorlin syndrome, is a rare autosomal dominant disorder caused by mutations in the tumor suppressor gene PTCH1 with complete penetrance and variable expressivity characterized by a broad spectrum of developmental anomalies and a predisposition to neoplasms. Herein, we report a novel de novo splice site mutation in the PTCH1 gene related to mild developmental delay and autistic traits in a 4-year-old male patient.

1 November 2025
Verified
Journal Article
Closed access
PMParisa Mashayekhi
Parisa Mashayekhi
MOMir Davood Omrani
Mir Davood Omrani
ADAli Dehghanifard
Ali Dehghanifard
AKAdnan Khosravi
Adnan Khosravi
MJMohammad Mehdi Jahani
Mohammad Mehdi Jahani
NKNegin Khosravi
Negin Khosravi